Neurocrine Biosciences reported $972.8M in Current Assets for its fourth fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Assets Change
Agios Pharmaceuticals AGIO:US $ 1064.23M 241.05M
Aptinyx Inc APTX:US $ 106.53M 8.22M
Cytokinetics CYTK:US $ 623.53M 87.85M
Enanta Pharmaceuticals ENTA:US $ 341.87M 14.91M
IONIS PHARMACEUT IONS:US $ 2345M 189.26M
Nektar Therapeutics NKTR:US $ 795.58M 190.55M
Prothena PRTA:US 555.62M 29.19M
Teva Pharmaceutical TEVA:IT 12.57B 419M
Xoma XOMA:US $ 89.61M 7.36M